Nanogene editing drug delivery systems in the treatment of liver fibrosis

被引:0
|
作者
Wang, Qun [1 ]
Jia, Siyu [1 ]
Wang, Zihan [1 ]
Chen, Hui [1 ]
Jiang, Xinyi [1 ]
Li, Yan [2 ]
Ji, Peng [1 ,3 ]
机构
[1] Taizhou Univ, Coll Pharm & Chem & Chem Engn, Taizhou, Peoples R China
[2] Dalian Med Univ, Dept Int Med, Hosp 2, Dalian, Peoples R China
[3] Zhejiang Univ, Sch Med, Liangzhu Lab, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
gene editing; delivery system; liver fibrosis; CRISPR-Cas9; nanoparticles; targeted therapy; HEAT-SHOCK-PROTEIN; GENE; DNA; NANOPARTICLES; CLEAVAGE; DISEASE; CELLS; BASE; GP96;
D O I
10.3389/fmed.2024.1418786
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Liver fibrosis is a group of diseases that seriously affect the health of the world's population. Despite significant progress in understanding the mechanisms of liver fibrogenesis, the technologies and drugs used to treat liver fibrosis have limited efficacy. As a revolutionary genetic tool, gene editing technology brings new hope for treating liver fibrosis. Combining nano-delivery systems with gene editing tools to achieve precise delivery and efficient expression of gene editing tools that can be used to treat liver fibrosis has become a rapidly developing field. This review provides a comprehensive overview of the principles and methods of gene editing technology and commonly used gene editing targets for liver fibrosis. We also discuss recent advances in common gene editing delivery vehicles and nano-delivery formulations in liver fibrosis research. Although gene editing technology has potential advantages in liver fibrosis, it still faces some challenges regarding delivery efficiency, specificity, and safety. Future studies need to address these issues further to explore the potential and application of liver fibrosis technologies in treating liver fibrosis.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Drug Delivery Systems for the Treatment of Ischemic Stroke
    Taiyoun Rhim
    Dong Yun Lee
    Minhyung Lee
    Pharmaceutical Research, 2013, 30 : 2429 - 2444
  • [42] NANOPARTICULATE DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF DIABETES
    Sona, P. S.
    DIGEST JOURNAL OF NANOMATERIALS AND BIOSTRUCTURES, 2010, 5 (02) : 411 - 418
  • [43] Drug delivery systems for treatment of systemic hypertension
    Prisant, LM
    Elliott, WJ
    CLINICAL PHARMACOKINETICS, 2003, 42 (11) : 931 - 940
  • [44] Liposomal drug delivery systems for the treatment of leishmaniasis
    Tuon, Felipe Francisco
    Dantas, Leticia Ramos
    de Souza, Regina Maia
    Tasca Ribeiro, Victoria Stadler
    Amato, Valdir Sabbaga
    PARASITOLOGY RESEARCH, 2022, 121 (11) : 3073 - 3082
  • [45] Efficient drug and gene delivery to liver fibrosis:rationale, recent advances, and perspectives
    Somayeh Mahdinloo
    Seyed Hossein Kiaie
    Ala Amiri
    Salar Hemmati
    Hadi Valizadeh
    Parvin Zakeri-Milani
    Acta Pharmaceutica Sinica B, 2020, 10 (07) : 1279 - 1293
  • [46] Efficient drug and gene delivery to liver fibrosis: rationale, recent advances, and perspectives
    Mahdinloo, Somayeh
    Kiaie, Seyed Hossein
    Amiri, Ala
    Hemmati, Salar
    Valizadeh, Hadi
    Zakeri-Milani, Parvin
    ACTA PHARMACEUTICA SINICA B, 2020, 10 (07) : 1279 - 1293
  • [47] Therapy of liver fibrosis: From conventional approaches to nanomaterials delivery systems
    Chen, Lin
    Duan, Yu
    Jiang, Tingting
    Mao, Chun
    Zhu, Xinhua
    Wan, Mimi
    SCIENCE BULLETIN, 2024, 69 (12) : 1829 - 1832
  • [48] Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis
    Peng, Wei
    Cheng, Shumin
    Bao, Zhihang
    Wang, Youjing
    Zhou, Wei
    Wang, Junxian
    Yang, Qingling
    Chen, Changjie
    Wang, Wenrui
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 137
  • [49] Drug delivery systems for the topical treatment of cutaneous leishmaniasis
    Carneiro, Guilherme
    Aguiar, Marta Gontijo
    Fernandes, Ana Paula
    Miranda Ferreira, Lucas Antonio
    EXPERT OPINION ON DRUG DELIVERY, 2012, 9 (09) : 1083 - 1097
  • [50] Advancing drug delivery systems for the treatment of multiple sclerosis
    Inna Tabansky
    Mark D. Messina
    Catherine Bangeranye
    Jeffrey Goldstein
    Karen M. Blitz-Shabbir
    Suly Machado
    Venkatesh Jeganathan
    Paul Wright
    Souhel Najjar
    Yonghao Cao
    Warren Sands
    Derin B. Keskin
    Joel N. H. Stern
    Immunologic Research, 2015, 63 : 58 - 69